HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David Oscier Selected Research

Leukemia

12/2012Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
12/2007Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David Oscier Research Topics

Disease

25B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/2022 - 02/2003
8Neoplasms (Cancer)
03/2017 - 02/2003
6Disease Progression
12/2019 - 02/2003
4Lymphoma (Lymphomas)
01/2019 - 11/2015
2Chromosome Aberrations (Chromosome Abnormalities)
01/2019 - 09/2010
2Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2018 - 10/2009
2Lymphocytosis
03/2017 - 02/2014
2Leukemia
12/2012 - 12/2007
2Polycythemia Vera
06/2009 - 04/2006
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2006 - 01/2003
1Trisomy (Trisomies)
09/2016
1Ataxia Telangiectasia (Louis Bar Syndrome)
08/2015
1Infections
05/2012
1Viremia
05/2012
1Primary Myelofibrosis (Myelosclerosis)
06/2009
1BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative)
06/2009
1Paraproteinemias (Monoclonal Gammopathy)
01/2009
1Polycythemia (Erythrocytosis)
06/2008
1Hematologic Neoplasms (Hematological Malignancy)
05/2008
1Refractory Anemia
07/2006
1Genetic Translocation (Chromosomal Translocation)
09/2005
1Myeloproliferative Disorders (Myeloproliferative Disorder)
09/2005
1Residual Neoplasm
05/2005

Drug/Important Bio-Agent (IBA)

9Immunoglobulins (Immunoglobulin)IBA
11/2021 - 01/2009
5fludarabineIBA
12/2019 - 06/2011
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2019 - 06/2011
5Biological ProductsIBA
01/2019 - 02/2003
3Biomarkers (Surrogate Marker)IBA
04/2022 - 10/2016
3Rituximab (Mabthera)FDA Link
12/2019 - 05/2012
3AntigensIBA
01/2019 - 04/2016
3DNA (Deoxyribonucleic Acid)IBA
01/2018 - 06/2005
2AntioxidantsIBA
08/2015 - 06/2005
2Chlorambucil (Leukeran)FDA Link
12/2012 - 06/2011
2Alemtuzumab (Campath)FDA Link
05/2012 - 05/2005
2Proteins (Proteins, Gene)FDA Link
05/2008 - 12/2005
1Complementarity Determining Regions (Complementarity Determining Region)IBA
01/2019
1olaparibIBA
01/2018
1RNA (Ribonucleic Acid)IBA
01/2018
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2018
1B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA
09/2016
1ChromatinIBA
01/2016
1Toll-Like Receptors (Toll-Like Receptor)IBA
11/2015
1Reactive Oxygen Species (Oxygen Radicals)IBA
08/2015
1Itraconazole (Sporanox)FDA LinkGeneric
05/2012
1ValganciclovirFDA Link
05/2012
1Acyclovir (Aciclovir)FDA LinkGeneric
05/2012
1MethylprednisoloneFDA LinkGeneric
05/2012
1Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric
05/2012
1Alkylating AgentsIBA
03/2012
1purineIBA
03/2012
1Hemoglobins (Hemoglobin)IBA
09/2010
1Histone MethyltransferasesIBA
08/2010
1MicroRNAs (MicroRNA)IBA
10/2009
1N 30IBA
06/2009
1ErythropoietinFDA Link
06/2008
1endothelial PAS domain-containing protein 1IBA
06/2008
1Oxygen (Dioxygen)IBA
06/2008
1Phosphotransferases (Kinase)IBA
05/2008
1Tyrosine (L-Tyrosine)FDA Link
05/2008
1RNA Precursors (Precursor, mRNA)IBA
05/2008
1Pharmaceutical PreparationsIBA
12/2007
1InterferonsIBA
07/2006
1Heme (Haem)IBA
07/2006
1Imatinib Mesylate (Gleevec)FDA Link
04/2006
1Interferon-alpha (Interferon Alfa)IBA
04/2006
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
09/2005
1UracilIBA
06/2005
1EnzymesIBA
06/2005
1AdenineFDA LinkGeneric
06/2005
1Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
06/2003
1Immunoglobulin M (IgM)IBA
02/2003
1Immunoglobulin Variable RegionIBA
02/2003

Therapy/Procedure

5Therapeutics
01/2018 - 01/2003
2Drug Therapy (Chemotherapy)
05/2012 - 12/2007
1Ligation
02/2003